CompletedNot Applicable

Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

Italy100 participantsStarted 2013-05

Plain-language summary

The study aims to evaluate the molecular mechanism underlying the erythroid response observed in some patients with myelodysplasia, myelofibrosis and aplastic anemia treated with Deferasirox or Deferoxamina.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients aged 18 and older
✓. Diagnosis of Myelodysplasia, myelofibrosis or aplastic anemia
✓. transfusion-dependent anemia undergoing chelation therapy with deferasirox or deferoxamine

What they're measuring

To assess the molecular mechanism underlying the erythroid response

Timeframe: 12 months

Trial details

NCT IDNCT01956799

SponsorFondazione Italiana Sindromi Mielodisplastiche-ETS

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-07

View on ClinicalTrials.gov More Myelodysplasia trials